User login
TOPLINE:
METHODOLOGY:
- This phase 3 multicenter, single-arm trial evaluated the safety and tolerability of tirbanibulin ointment 1% in 105 adults with 4-12 clinically typical, visible, and discrete AKs on the face or balding scalp from June to December 2022 in the United States. (In June 2024, the Food and Drug Administration approved a supplemental new drug application for tirbanibulin 1%, a microtubule inhibitor, allowing the expansion of the surface area treated for AKs of the face or scalp from 25 cm2 to 100 cm2.)
- Participants applied tirbanibulin ointment 1% once daily for 5 days over a treatment field of about 100 cm2 on the face or balding scalp. A total of 102 patients completed the study.
- Safety and tolerability were evaluated with reports of treatment-emergent adverse events (TEAEs) and a composite score of six local tolerability signs on days 5, 8, 15, and 29, and on completion of the evaluation period on day 57.
TAKEAWAY:
- The most common local effects of treatment were erythema (96.1% of patients) and flaking or scaling (84.4%), with severe cases reported in 5.8% and 8.7% of the patients, respectively.
- The mean maximum local tolerability composite score was 4.1 out of 18, which peaked around day 8 and returned to baseline by day 29.
- TEAEs considered related to the treatment were reported in 18.1% of patients; the most frequent were application site pruritus (10.5%) and application site pain (8.6%). No adverse events led to the discontinuation of treatment.
- The mean percent reduction in the lesion count from baseline was 77.8% at day 57, with a mean lesion count of 1.8 at the end of the study.
IN PRACTICE:
In this study, “local tolerability and safety profiles were well characterized in patients with 4-12 clinically typical, visible, and discrete AK lesions in a field of 100 cm2 and were consistent with those previously reported in patients with AK treated in pivotal trials with tirbanibulin over a smaller field (25 cm2),” the authors wrote.
SOURCE:
The study, led by Neal Bhatia, MD, of Therapeutics Clinical Research, San Diego, was published online in JAAD International.
LIMITATIONS:
The study was limited by the lack of a placebo group and the absence of long-term follow-up.
DISCLOSURES:
This study was funded by Almirall. Five authors reported being employees of Almirall. Other authors declared having ties with various other sources, including Almirall.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication. A version of this article first appeared on Medscape.com.
TOPLINE:
METHODOLOGY:
- This phase 3 multicenter, single-arm trial evaluated the safety and tolerability of tirbanibulin ointment 1% in 105 adults with 4-12 clinically typical, visible, and discrete AKs on the face or balding scalp from June to December 2022 in the United States. (In June 2024, the Food and Drug Administration approved a supplemental new drug application for tirbanibulin 1%, a microtubule inhibitor, allowing the expansion of the surface area treated for AKs of the face or scalp from 25 cm2 to 100 cm2.)
- Participants applied tirbanibulin ointment 1% once daily for 5 days over a treatment field of about 100 cm2 on the face or balding scalp. A total of 102 patients completed the study.
- Safety and tolerability were evaluated with reports of treatment-emergent adverse events (TEAEs) and a composite score of six local tolerability signs on days 5, 8, 15, and 29, and on completion of the evaluation period on day 57.
TAKEAWAY:
- The most common local effects of treatment were erythema (96.1% of patients) and flaking or scaling (84.4%), with severe cases reported in 5.8% and 8.7% of the patients, respectively.
- The mean maximum local tolerability composite score was 4.1 out of 18, which peaked around day 8 and returned to baseline by day 29.
- TEAEs considered related to the treatment were reported in 18.1% of patients; the most frequent were application site pruritus (10.5%) and application site pain (8.6%). No adverse events led to the discontinuation of treatment.
- The mean percent reduction in the lesion count from baseline was 77.8% at day 57, with a mean lesion count of 1.8 at the end of the study.
IN PRACTICE:
In this study, “local tolerability and safety profiles were well characterized in patients with 4-12 clinically typical, visible, and discrete AK lesions in a field of 100 cm2 and were consistent with those previously reported in patients with AK treated in pivotal trials with tirbanibulin over a smaller field (25 cm2),” the authors wrote.
SOURCE:
The study, led by Neal Bhatia, MD, of Therapeutics Clinical Research, San Diego, was published online in JAAD International.
LIMITATIONS:
The study was limited by the lack of a placebo group and the absence of long-term follow-up.
DISCLOSURES:
This study was funded by Almirall. Five authors reported being employees of Almirall. Other authors declared having ties with various other sources, including Almirall.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication. A version of this article first appeared on Medscape.com.
TOPLINE:
METHODOLOGY:
- This phase 3 multicenter, single-arm trial evaluated the safety and tolerability of tirbanibulin ointment 1% in 105 adults with 4-12 clinically typical, visible, and discrete AKs on the face or balding scalp from June to December 2022 in the United States. (In June 2024, the Food and Drug Administration approved a supplemental new drug application for tirbanibulin 1%, a microtubule inhibitor, allowing the expansion of the surface area treated for AKs of the face or scalp from 25 cm2 to 100 cm2.)
- Participants applied tirbanibulin ointment 1% once daily for 5 days over a treatment field of about 100 cm2 on the face or balding scalp. A total of 102 patients completed the study.
- Safety and tolerability were evaluated with reports of treatment-emergent adverse events (TEAEs) and a composite score of six local tolerability signs on days 5, 8, 15, and 29, and on completion of the evaluation period on day 57.
TAKEAWAY:
- The most common local effects of treatment were erythema (96.1% of patients) and flaking or scaling (84.4%), with severe cases reported in 5.8% and 8.7% of the patients, respectively.
- The mean maximum local tolerability composite score was 4.1 out of 18, which peaked around day 8 and returned to baseline by day 29.
- TEAEs considered related to the treatment were reported in 18.1% of patients; the most frequent were application site pruritus (10.5%) and application site pain (8.6%). No adverse events led to the discontinuation of treatment.
- The mean percent reduction in the lesion count from baseline was 77.8% at day 57, with a mean lesion count of 1.8 at the end of the study.
IN PRACTICE:
In this study, “local tolerability and safety profiles were well characterized in patients with 4-12 clinically typical, visible, and discrete AK lesions in a field of 100 cm2 and were consistent with those previously reported in patients with AK treated in pivotal trials with tirbanibulin over a smaller field (25 cm2),” the authors wrote.
SOURCE:
The study, led by Neal Bhatia, MD, of Therapeutics Clinical Research, San Diego, was published online in JAAD International.
LIMITATIONS:
The study was limited by the lack of a placebo group and the absence of long-term follow-up.
DISCLOSURES:
This study was funded by Almirall. Five authors reported being employees of Almirall. Other authors declared having ties with various other sources, including Almirall.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication. A version of this article first appeared on Medscape.com.